Wait begins for Protara data
Gensia Inc. on Friday announced that it has completed enrollment of its third Phase III trial of Protara (acadesine) in patients undergoing coronary artery bypass graft surgery. The decision was in accordance with the trial's clinical protocol based on group sequential analysis.
Tea leaf readers will have 10 weeks to sift for meanings, while GNSA collects and analyzes the data on its adenosine regulating agent. If the results are favorable, the San Diego company will submit the data in the fourth